Global pharmaceutical investment in China’s biotech sector surged to unprecedented levels in the first half of 2025, with total deal value already reaching $48.5 billion—surpassing the entire sum spent throughout 2024. According to new analysis from IQVIA, the volume and value of cross-border deals between global pharma giants and Chinese biotech innovators highlight both the maturation of China’s pharmaceutical R&D ecosystem and the growing global appetite for cost-effective, innovative therapies emerging from the region.

The first six months of 2025 witnessed 61 agreement signings, already outpacing the 100-plus deals made throughout 2024 if current trends continue. Notably, 37 of these involved U.S.-based partners, indicating a growing willingness among American companies to tap into Chinese-originated assets—driven by the urgency to accelerate pipelines and meet the demands of oncology and immunological research. The number of U.S.-centric deals rose to 61% for H1 2025, a significant increase from 37% in the previous year, reflecting shifting dynamics in international pharma collaboration.

The nature of these deals demonstrates an increasing tendency toward heavily backloaded agreements. Many multinationals are now providing Chinese partners with substantial upfront capital in exchange for early research and clinical data, while deferring substantial milestone payments until candidate assets are significantly de-risked. In total, 16 deals exceeded $1 billion in value in H1 2025 alone, matching the entirety of last year, and five surpassed $3 billion.

Key transactions included Pfizer’s headline $1.25 billion upfront payment, $100 million in equity, and $4.8 billion in potential milestones for 3SBio’s Phase III-ready bispecific antibody targeting PD-1 and VEGF—demonstrating continued Western interest in next-generation cancer drugs. AstraZeneca also inked multiple agreements worth a combined $4.68 billion with Harbour BioMed for multispecific antibodies, further reflecting industry focus on oncology and immunology.

From the Chinese perspective, global dealmaking validates domestic innovation while providing critical funding for pipeline advancement. These investments essentially offer Chinese biotechs both international credibility and the resources required for accelerated development. Oncology continued its dominance as the most sought-after therapeutic area, with immunological and inflammatory disease assets also rising in deal value and frequency—a trend anticipated to persist as the global burden of chronic and complex diseases grows.

Despite concerns about geopolitical pressures potentially hindering such large-scale collaboration, IQVIA’s report asserts that data so far does not show significant negative impacts. The market’s momentum is further amplified by strategic considerations, as former U.S. FDA commissioner Scott Gottlieb recently warned that waning U.S. biomedical dominance could cede critical technological ground to China—highlighting just how influential these partnerships have become in shaping the future of biopharmaceutical innovation on both sides of the Pacific.

For pharmaceutical executives, R&D leaders, and business development teams, this surge in cross-border dealmaking carries urgent strategic implications. The willingness of multinationals to enter complex, high-value partnerships in the Asian market—particularly with an emphasis on risk-sharing and late-stage asset validation—underscores the necessity of sophisticated due diligence, dynamic alliance management, and agile regulatory planning. As more global pharma companies revisit their China strategies, these trends are expected to redefine the competitive landscape of contract drug discovery, manufacturing, clinical trial outsourcing, and advanced therapeutic development far beyond 2025.